Storm Therapeutics discovers and develops small molecule drugs that target RNA-modifying enzymes, for treatment of cancer.
Several large families of RNA-modifying enzymes have been identified that impact key biological processes by changing the activity of RNA through catalysing epigenetic RNA modifications. Advances in the understanding of RNA modification and its role in the development of cancer offer the prospect of exploring novel therapeutic targets and potential discovery and development of first-in-class products. STORM is working in this new field.
|Employees (est.) (Jan 2020)||29|
Storm Therapeutics total Funding
Storm Therapeutics latest funding size
Time since last funding
|2 years ago|
Storm Therapeutics investors
|Imperial Innovations, Pfizer Venture Investments, Merck Ventures, Touchstone Innovations, Cambridge Innovation Capital plc, Taiho Ventures|
|GBP||FY, 2015||FY, 2016||FY, 2017||FY, 2018|
When was Storm Therapeutics founded?
Storm Therapeutics was founded in 2015.
Who are Storm Therapeutics key executives?
Storm Therapeutics's key executives are Keith Blundy, Oliver Rausch and Wesley Blackaby.
How many employees does Storm Therapeutics have?
Storm Therapeutics has 29 employees.
Who are Storm Therapeutics competitors?
Competitors of Storm Therapeutics include Sareum Holdings, Cybrexa Therapeutics and Tiltan Pharma.
Where is Storm Therapeutics headquarters?
Storm Therapeutics headquarters is located at Babraham Research Campus, Cambridge.
Where are Storm Therapeutics offices?
Storm Therapeutics has offices in Cambridge and Greater London.
How many offices does Storm Therapeutics have?
Storm Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies